Company intelligence / Profile preview
Cocrystal Pharma
Bothell, Washington, United Statescocrystalpharma.com ↗
- Ownership
- Public · COCP
- Development stage
- Phase 2
01
Overview
Cocrystal Pharma is advancing several antiviral programs, including an oral PB2 inhibitor for influenza and a pan-viral protease inhibitor for norovirus and coronavirus. Recent Phase 1 results for CDI-988 showed favorable safety and tolerability.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Kansas State University Research Foundation
04
Financials
- Market cap
- $16.3M
- Total revenue
- $105K
- Enterprise value
- $15.4M
Beyond the preview
Go deeper on Cocrystal Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cocrystal Pharma.